NAD+ human trials — what the evidence actually shows

NAD+ supplements are sold on a promise — more energy, slower aging, a longer healthspan. The honest version is narrower and more interesting. A handful of real randomized human trials of the NAD+ precursors NR and NMN have now been published, and they converge on one finding that is genuinely well-replicated: these molecules raise blood NAD+ and are well-tolerated over weeks to months. What those same trials do not yet show is the part the marketing leans on hardest. This article walks the actual studies, names them, and keeps the two apart.

The one thing that is clearly true

If you strip the NAD+ category down to its single most-replicated human finding, it is this: oral precursors raise the NAD+ you can measure in blood, and they do it without obvious short-term harm. This is not a hopeful extrapolation from mouse data — it is what the controlled human trials repeatedly report, in healthy volunteers and in defined patient groups, across both NR and NMN, in a dose-dependent fashion.

That matters because it is the foundational claim everything else rests on. A precursor that did not actually raise NAD+ in people would make the whole longevity thesis moot. The trials clear that first bar convincingly. The mistake is treating “it raises NAD+” as if it were the same statement as “it does the thing you want NAD+ for.” Those are two different claims with two very different levels of evidence behind them — and the rest of this article keeps separating them.

Established: precursors raise blood NAD+ and are well-tolerated short-term. Not established: that the higher NAD+ makes a healthy person live longer or healthier. Hold those apart and the literature reads honestly.

The NR trials

Nicotinamide riboside (NR) was first to commercial scale and has the longest human paper trail. The foundational pharmacokinetic study is Trammell and colleagues (2016, Nature Communications), the first carefully-controlled human report on oral NR. Single doses of 100, 300, and 1000 mg produced a clear dose-dependent rise in the blood NAD+ metabolome, and the work identified nicotinic acid adenine dinucleotide (NAAD) as a sensitive biomarker that NAD+ stores had actually moved [1]. This is the study that established, in humans, that swallowing NR translates into a measurable NAD+ signal.

Martens and colleagues (2018, Nature Communications) extended that from a single dose to chronic use. In a placebo-controlled crossover design — two six-week arms in healthy middle-aged and older adults — chronic NR was well-tolerated and effectively elevated NAD+. The trial also reported a preliminary signal toward lower blood pressure and reduced arterial stiffness, which the authors framed cautiously as exploratory [2]. Read that signal carefully: it is a preliminary cardiovascular readout from a small early trial, the kind of finding that justifies a larger study, not a claim that NR lowers blood pressure as an established effect.

The most ambitious NR study is NADPARK (Brakedal and colleagues, 2022, Cell Metabolism): a double-blind phase I trial in 30 newly-diagnosed Parkinson’s patients given 1000 mg NR for 30 days. It raised cerebral NAD+ (variably between individuals), shifted cerebral metabolism, and was associated with mild clinical change — enough that the authors nominated the compound for further study. The framing here is non-negotiable: NADPARK is early-phase research in a neurological-disease population, explicitly a step toward a larger trial, and not evidence that NR is a treatment for Parkinson’s or anything else [3]. It belongs in this article because it is a real, well-designed human NAD-precursor trial — and because phase I means exactly what it says.

The NMN trials

Nicotinamide mononucleotide (NMN) sits one enzymatic step closer to NAD+ and has a newer but rapidly-growing human literature. The most-cited NMN trial is Yoshino and colleagues (2021, Science): a 10-week placebo-controlled RCT in postmenopausal women with prediabetes. NMN increased skeletal-muscle insulin sensitivity and upregulated muscle insulin-signalling and remodelling pathways [4]. State that precisely: it is a research finding about a specific tissue measure, in a specific, defined population, over ten weeks. It is not a claim that NMN treats diabetes, and the trial did not test or report that.

Yi and colleagues (2022, GeroScience) provides the dose-finding picture: a randomized trial in 80 healthy middle-aged adults across 300, 600, and 900 mg/day. Blood NAD+ rose at all three doses, NMN was safe and well-tolerated up to 900 mg/day, and the higher-dose groups showed a signal on the six-minute walk test — a standard functional-capacity measure [5]. This trial is useful precisely because it does two honest things at once: it confirms the reliable part (NAD+ rises, dose-dependent, safe to 900 mg) and reports a functional signal as a signal, not a settled outcome.

Notice the pattern across both NR and NMN: the NAD+-rise-and-safety finding repeats trial after trial. The functional and clinical signals appear in individual trials, in specific populations, and need replication before they become claims.

The honest gap

Here is the part the category’s marketing tends to skip. Two things are genuinely established in humans: precursors raise blood NAD+, and the doses studied are well-tolerated over the trial windows reported. Almost everything else is still open. The review by Rajman, Chwalek and Sinclair (2018, Cell Metabolism) framed this gap clearly even at the field’s commercial inflection point — the preclinical promise of NAD+ boosting was large, and the rigorous human evidence was, and largely remains, early [6].

• The trials are small and short. Most enroll dozens, not thousands, and run weeks to a few months. Longevity and durable healthspan are decade-scale questions; no published precursor trial has run anywhere near that long.
• Endpoints are mostly biomarkers and early functional measures. Blood NAD+, insulin sensitivity in one tissue, a walk-test distance, a blood-pressure signal. These are reasons to do bigger studies — not hard clinical outcomes like disease incidence or mortality in healthy people.
• Signals are not yet replicated into claims. A finding in prediabetic postmenopausal women, or in newly-diagnosed Parkinson’s patients, does not generalize to a healthy adult buying capsules. Each promising signal is, at this stage, a single study awaiting confirmation.
• The core leap is unmade. “NAD+ declines with age” and “precursors raise NAD+” are both true. “Therefore raising NAD+ makes you live healthier longer” is the inference the trials have not yet demonstrated in humans. That gap is the whole game.

Related reading in the NAD+ cluster

For how the three precursors differ — and why NMN and NR dominate the human literature while oral NAD+ itself does not — see NAD+ vs NMN vs NR. For the sirtuin and salvage-pathway biology behind why raising NAD+ is thought to matter, see NAD+ mechanism research. The category overview, including the UAE market, lives in the NAD+ in the UAE parent guide. Browse the research peptides in the UAE hub, or the NAD+ 100 mg research vial.

Further reading

Peer-reviewed citations used inline:

• [1] Trammell, et al. — Nat Commun 2016. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans; single doses raise the blood NAD+ metabolome dose-dependently. DOI 10.1038/ncomms12948.
• [2] Martens, et al. — Nat Commun 2018. Chronic NR is well-tolerated and effectively elevates NAD+ in healthy middle-aged and older adults; preliminary blood-pressure / arterial-stiffness signal. DOI 10.1038/s41467-018-03421-7.
• [3] Brakedal, et al. — Cell Metab 2022. The NADPARK study: double-blind phase I NR in newly-diagnosed Parkinson’s disease (early-phase research, not a treatment). DOI 10.1016/j.cmet.2022.02.001.
• [4] Yoshino, et al. — Science 2021. NMN increases muscle insulin sensitivity and signalling in prediabetic postmenopausal women (10-week RCT). DOI 10.1126/science.abe9985.
• [5] Yi, et al. — GeroScience 2022. NMN dose-finding RCT in 80 middle-aged adults; dose-dependent NAD+ rise, safe to 900 mg, six-minute-walk signal. DOI 10.1007/s11357-022-00705-1.
• [6] Rajman, Chwalek & Sinclair — Cell Metab 2018. Therapeutic potential of NAD-boosting molecules; review framing the gap between preclinical promise and early human evidence. DOI 10.1016/j.cmet.2018.02.011.

This article was last reviewed on 11 June 2026, and is general research-education content — not medical advice. We update it when major NAD-precursor trials publish. Wellness Labs supplies NAD+ as a research-grade preparation for non-clinical investigation. If you spot an error or a study we should incorporate, the editorial inbox is info@uaewellnesslab.com.